CMS could pay certain eligible hospitals approximately $9 billion in total as part of its plan to remedy unlawful cuts to the 340B drug discount program between 2018 and 2022, according to a proposed rule. However, the remedy would come at the cost of cuts to non-drug items and services...Read More »
Hospitals have made significant efforts to comply with price transparency regulations due to increased civil monetary penalties from CMS, according to a recent JAMA Network Open study.Read More »
CMS is proposing a coverage pathway to achieve expedited and more predictable access to new medical technologies for Medicare beneficiaries.Read More »
As part of 2023 Revenue Integrity Week (June 5-9), NAHRI opened nominations to its Peer Recognition Program to recognize revenue integrity professionals for their contributions to the field and for the ways in which they have helped their peers. Learn more about the nominees.Read More »
CMS recently released a list of the 43 Part B drugs and biologicals that will be included in the Medicare Prescription Drug Inflation Rebate Program for July 1–September 30.Read More »
A bipartisan group of over 30 senators recently wrote a letter to CMS to ask the agency to reevaluate the fiscal year (FY) 2024 Inpatient Prospective Payment System (IPPS) proposed rule.Read More »
